Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Bladder Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured

Published in Bladder Cancer and

Expert Opinion / Commentary · December 23, 2021

2021 Top Story in Bladder Cancer: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Written by

Shilpa Gupta MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

References

Notice to Our Valued Users

Bladder Cancer

2021 Top Story in Bladder Cancer: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Additional Info

Further Reading

Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma

Safety and Efficacy of WST-11 (TOOKAD Soluble) Vascular-Targeted Photodynamic Therapy in Patients With UTUC

NAT10 Drives Cisplatin Chemoresistance by Enhancing ac4C-Associated DNA Repair in Bladder Cancer

Role of Cell-Free Urine and Plasma DNA Mutation Analysis in Predicting Neoadjuvant Chemotherapy Response and Outcomes in Patients With MIBC

DFS Analysis in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma Using PD-L1 Combined Positive Score and Tumor Cell Score

AI-Based Model for Detecting Lymph Node Metastases in Patients With Bladder Cancer

Assessment of Survival Advantage of Radical Cystectomy in Patients With Adenocarcinoma of the Bladder vs Urothelial Bladder Cancer

Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Therapy vs BCG Therapy in Patients With High-Risk Non–Muscle-Invasive Bladder Cancer

Outcomes of En Bloc Resection vs Conventional TURBT in Patients With T1 High-Grade Bladder Cancer

Efficacy of High- and Low-Dose Preoperative Ipilimumab Plus Nivolumab in Patients With Stage III Urothelial Cancer

Recently Updated